ArticleScientific reports2026
Bioactive secretory leukocyte protease inhibitor (SLPI)-derived short peptides (SDSPs) attenuate LPS-induced inflammatory responses in macrophages.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Inflammation is a crucial defence mechanism against infections and harmful stimuli. However, uncontrolled inflammation can lead to low-grade inflammatory conditions that disrupt tissues and systemic function. Anti-inflammatories relieve symptoms. However, it can cause side effects and lack targeted control. These limitations are addressed by “peptide-based therapeutics.” The secretory leukocyte protease inhibitor (SLPI) has anti-inflammatory effects. However, SLPI has a short half-life and low cellular uptake. Using short peptides is a promising therapeutic strategy due to their small size, high effectiveness, and low immunogenicity. This research investigates the anti-inflammatory effect of SLPI-derived short peptides (SDSPs). SLPI was enzymatically digested in silico to produce SDSPs. The physiological properties of SDSPs and their anti-inflammatory activities in an LPS-induced RAW 264.7 cell inflammatory model were examined. Digested fragments, including 11 from pepsin (P1-11) and 9 from trypsin (T1-T9) digestion, plus the N-terminal fragment, were obtained. SDSPs are diverse physiological properties, and some are anti-inflammatory peptides (AIPs). Determination in the LPS-induced macrophage inflammation model found four potential SDSPs, specifically T6, T7, T8, and P7, exhibit anti-inflammatory properties by reducing excessive ROS generation and the activation of the MAPK/NF-κB pathway, similar to SLPI. This study identifies possible candidates for anti-inflammatory medicines warranting further investigation in in vivo and clinical trials for inflammation-related disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.